

REMARKS

First, Applicant's note with appreciation the indication that Claims 9-18 have been allowed (pg. 3, para. 5 of the Official Action). We note, however, that Claims 9 and 10 each depend from independent Claim 1, which claim has been rejected. Accordingly, Claims 9 and 10 have been rewritten in independent form to include the limitations of Claim 1. Accordingly, it is respectfully submitted that Claims 9 and 10 are in condition for allowance. Further, Claims 11-18 depend either directly or indirectly from Claim 10 and are therefore also in condition for allowance.


Applicants also note with appreciation the indication that Claims 2, 6 and 8 contain allowable subject matter (pg. 3, para. 4 of the Official Action). In particular, these claims have been objected to as being dependent upon a rejected base claim but have been indicated to be allowable if rewritten in independent form. Accordingly, these claims have been rewritten in independent form to include the limitations of Claim 1. Accordingly, it is respectfully submitted that Claims 2, 6 and 8 are now in condition for allowance.

Claims 1, 3, 4, 5 and 7 were rejected under 35 U.S.C. §102(b) as allegedly being anticipated by JP-57-212457 or Conn et al., "Convergent Functional Groups. 13. High-Affinity Complexation of Adenosine Derivatives Within Induced Binding Pockets", J. Am. Chem. Soc., 115:3548-57 (1993) (hereinafter referred to as "Conn"). Claims 1, 3 and 7 were rejected under 35 U.S.C. §102(b) as allegedly being anticipated by U.S. Patent No. 6,177,240 B1 to Yamada et al. (hereinafter referred to as "Yamada") or Shukla, "Synthesis Of Some New Aryl α -(3)Substituted-Carbazol-9-YL) Acetates/Propionates As Possible Antiinflammatory And Analgesic Agents", Indian J. Chem., 33B:799-802 (1994) (hereinafter referred to as "Shukla").

Claim 1 has been canceled without prejudice or disclaimer. In addition, Claims 3 and 7 have been amended to depend from Claim 6. Further, Claims 4 and 5 be amended to depend

from Claim 2. Claims 2 and 6 have been indicated to contain allowable subject matter and have been rewritten in independent form. Accordingly, it is respectfully submitted that Claims 3, 4, 5 and 7 are patentable over the references cited in the Official Action.

Claims 19 and 20 have been added. It is respectfully submitted that the subject matter of these claims is patentable over the references cited in the Official Action. In particular, Claims 19 and 20 recite carbazole derivatives of the following formula (1),



wherein:

I) R^1 and R^2 individually represent a hydrogen atom or a monovalent organic group with the proviso that either of R^1 or R^2 is an ethyl group, and R^3 represents a hydrogen atom or a monovalent organic group (Claim 19); or

II) R^1 and R^2 individually represent a hydrogen atom or a monovalent organic group with the proviso that either of R^1 or R^2 is a phenyl group, and R^3 in the formula (1) is a linear, branched, or cyclic alkyl group having 1-12 carbon atoms, an aromatic hydrocarbon group having 6-20 carbon atoms, an oxygen-containing organic group, a nitrogen-containing organic group, or an acid-dissociable organic group (Claim 20).

It is respectfully submitted that carbazole derivatives as defined by definitions (I) and (II) above are neither taught nor suggested by the references cited in the Official Action.


Accordingly, Claims 19 and 20 are patentable over the references cited in the Official Action.

CONCLUSION

Applicants submit that all of the pending claims of this application are now in condition for allowance and respectfully request that the Examiner take action indicating the same. If any points remain at issue, however, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

Respectfully submitted,

PIPER RUDNICK LLP

A handwritten signature in black ink, appearing to read 'S. Kelber', is written over a horizontal line.

Steven B. Kelber
Registration No. 30,073
Attorney of Record

1200 Nineteenth Street, N.W.
Washington, D.C. 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Christopher W. Raimund
Registration No. 47,258